Multiple Sclerosis (MS) Drug Market

Benzinga  1 hr ago  Comment 
Receptos (NASDAQ: RCPT) closed Monday just short of a 52-seek high after an analyst suggested the drug development company could become a takeover candidate. Receptos is developing drugs for a range of immune system disorders including its...
FierceBiotech  Aug 18  Comment 
Billing it as the most important new innovation in the interferon drug class in a decade, Biogen Idec nailed down the FDA's approval of Plegridy, a new multiple sclerosis drug that patients can easily inject themselves with once every two weeks.
MedPage Today  Aug 16  Comment 
(MedPage Today) -- A pegylated form of interferon-beta-1a (Plegridy) that can be administered once every 2 weeks in patients with relapsing multiple sclerosis was approved by the FDA, its manufacturer said.
DailyFinance  Aug 15  Comment 
Today Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved PLEGRIDYTM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis (RMS)....
TechCrunch  Aug 13  Comment 
 Dude, where’s my car? Back in the garage because you took an Uber rather than driving high. At least that’s the idea behind leading “Yelp for marijuana” service WeedMaps and Colorado pot shop The Clinic partnering with Uber. Each time a...
MedPage Today  Aug 8  Comment 
(MedPage Today) -- Recent studies linked vitamin D deficiency with dementia risk and multiple sclerosis with intestinal microbiome activity, and a prostaglandin receptor may be a viable drug target in ALS.
New York Times  Aug 1  Comment 
A man with multiple sclerosis is helped by an experimental treatment, but must do battle with his insurer over who will pay.
FiercePharma  Jul 23  Comment 
For Biogen Idec's second quarter, multiple sclerosis star Tecfidera blew analysts' estimates out of the water, as it's been wont to do. But it wasn't Tecfidera alone that helped the Massachusetts biotech trounce sales estimates by about $250 million.  Jul 17  Comment 
WASHINGTON (dpa-AFX) - Alkermes plc (ALKS) Thursday said it has begun its phase 1 clinical trial of ALKS 8700, an investigational monomethyl fumarate molecule, for the treatment of multiple sclerosis. The double -blind study will evaluate the...
Benzinga  Jul 9  Comment 
Biogen Idec (NASDAQ: BIIB) moved up a bit after a Deutsche Bank analyst on Wednesday talked up prospects for one of its multiple sclerosis drug candidate. If the drug gets marketing approval "the stock could move up by $30 to $100 in a single...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki